January 19, 2010

Press Release

Mitsubishi Tanabe Pharma Corporation

Approval for New Dosage Form of RADICUT®, Cerebral Neuroprotectant "RADICUT® BAG for I.V. infusion 30mg"

Osaka, Japan, January 19, 2010 ----Mitsubishi Tanabe Pharma Corporation (President & CEO, Michihiro Tsuchiya) announced today that the Company received, as of January 15, 2010, approval for the manufacture and marketing of "RADICUT® BAG for I.V. infusion 30 mg," a new dosage form of "RADICUT® injection 30 mg (generic name: edaravone), a cerebral neuroprotectant.

RADICUT® was marketed by the Company in June 2001 as the world's first cerebral neuroprotectant (free-radical scavenger) shown to improve neurological symptoms, interference with activities of daily living and functional disability in acute ischemic stroke. It has since been administered to many patients as the standard medical therapy in acute ischemic stroke.

It is important for the treatment of acute ischemic stroke that a medical team comprising doctors, nurses, pharmacists and other medical staff exerts its skills within a limited time as a team. Medical professionals in this team play a very important role, deciding treatment policy promptly after the patient is brought to the hospital and preparing drugs to be administered. Accordingly, there has been demand for the development of convenient drug forms that can reduce the burden on medical professionals and that can be administered easily. RADICUT® BAG for I.V. infusion 30 mg is a very convenient drug that satisfies these needs on the medical front.

The Company will promote early penetration of RADICUT® BAG for I.V. infusion 30 mg after its launch on the market, with the aim of contributing to treatment of acute ischemic stroke, which requires prompt medical action, while establishing the Company's strong position as a leading company in the medical therapy of stroke.

For Further Details, Contact

Corporate Communications Dept., Mitsubishi Tanabe Pharma Corporation

Tel +81-6-6205-5211